Head of Clinical Epidemiology
CSL Behring, King of Prussia, PA, USA
Collegeville, United States
Quazi Ataher, MBBS, MHS, PhD is the Head of Clinical Epidemiology at CSL Behring. He is a physician with a PhD in epidemiology and has nearly two decades of experience in the application of pharmacoepidemiology scientific principles and observational research using real world data. He has led and supervised numerous observational studies for the generation of real-world evidence focusing on the safety and benefit-risk assessment of medicines in diverse therapeutic areas for regulatory decision making.
In addition to his technical expertise in the realm of observational studies, Quazi has deep insights into the regulatory agency rules, guidance and expectations related to safety assessment of medicines. His insights were instrumental in the development and revision of multiple relevant SOPs in the company to be optimally compliant with the requirements of various agencies. At CSL Behring he co-chairs the technical review committee for all observational study projects and provides epidemiological expertise for the company’s safety management. He has a passion for benefit-risk assessment methods and patient preference research and was the industry co-lead for work package 4: Recommendations of the Innovative Medicine's Initiative's PREFER project on patient preference research.
He enjoys mentoring pharmacoepidemiologists entering the field. An active member of ISPE, he is the co-chair of the Cell and Gene Therapy SIG and a past-chair of the Membership Committee.
Disclosure information not submitted.
Friday, August 25, 2023
3:30 PM – 5:00 PM ADT
